10 PACK GLP-3R (RETA) 10 mg

10 mg Retatrutide (10 Pack) (also known as LY3437943) is an experimental injectable peptide currently under clinical investigation. It is distinguished by its unique "triple agonist" mechanism, acting on three different hormone receptors to regulate metabolism.

Here is a summary of its primary attributes based on recent clinical research:

Triple Agonist Mechanism

Unlike existing treatments that target one or two receptors, retatrutide targets three:

• GLP-1 (Glucagon-like peptide-1): Enhances insulin secretion and slows gastric emptying to increase fullness.
• GIP (Glucose-dependent insulinotropic polypeptide): Improves insulin sensitivity and lipid metabolism while reducing nausea often associated with GLP-1.
• GCGR (Glucagon receptor): Increases energy expenditure (calorie burning) and directly targets liver fat metabolism.
• Human trials have shown massive improvements in metabolic function, lipid profiles, and reduction in A1C glucose profiles, and fat reduction.